Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

420 with CNW — New Study Says Stress Drives Riskier Marijuana Use in Youth

A recent Canadian study focused on marijuana use among young adults offers insights into which behaviors and personal characteristics are linked to higher risks of marijuana-related problems.

While not all marijuana use results in negative outcomes, around 5% of young users in Canada may experience addiction or other harmful effects. What separates those who face issues from those who do not often comes down to how and why marijuana is used.

The study found that certain habits were linked to a higher risk of problems. These included using marijuana when alone, using it frequently throughout the week, consuming large amounts at once, or turning to it as a way to escape from stress or negative emotions. People who used marijuana to make everyday activities more enjoyable or to explore new experiences also tended to report more issues.

These findings line up with other research, especially the idea that frequent use and using alone are warning signs.

The study also found that not all groups of young adults face the same level of risk. Young people who identify as queer, lesbian, bisexual, gay, or otherwise sexually diverse reported more frequent and riskier patterns of marijuana use than their heterosexual peers. They were about three times more likely to fall into these higher-risk categories.

This increased risk was not attributed to sexual identity itself but to the elevated stress levels reported by these groups. Although higher rates of depression and anxiety were also noted among sexually diverse youth, general stress, particularly feelings of being overwhelmed or out of control, was the strongest predictor of problematic marijuana use. These stressors go beyond those caused by discrimination and point to broader life challenges that disproportionately affect marginalized groups.

This connects to a larger concept known as “minority stress”— the added stress that comes from being marginalized. Discrimination, exclusion, and internalized negativity can take a toll, and marijuana can become a way to cope.

With rising hostility toward LGBTQ+ communities in both the U.S. and Canada, the stress-related gaps in marijuana use may grow wider, according to the researchers.

Access to mental health care remains another barrier. Many sexually diverse youths face obstacles when trying to find safe, inclusive, and effective support services. As a result, marijuana may become a primary coping tool in the absence of better alternatives.

The study emphasizes the importance of making low-risk marijuana use strategies accessible, such as limiting frequency, avoiding solitary use, reducing quantities, and developing healthier coping mechanisms. However, these strategies are only effective if young people, especially those from marginalized backgrounds, have real access to supportive resources.

As the cannabis industry continues to grow and create numerous opportunities for other companies like Innovative Industrial Properties Inc. (NYSE: IIPR) exploiting opportunities within the marijuana ecosystem, more studies will be required to understand the drivers behind the use of this substance and how those who develop unhealthy usage habits can be helped.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — How Firms Can Manage the Challenges Arising from Marijuana Ad Restrictions

Running advertisements in the cannabis industry isn’t as straightforward as it is for other sectors. Business owners face a maze of regulations that make promoting their products difficult. These rules are often seen as restrictions on free speech because they limit what companies can say about their products, even when the information is accurate and meant for adults.

Many states with legal cannabis have strict advertising rules based on public health concerns. Authorities worry that ads could mislead or confuse people. To minimize this risk, they place limits on the language and visuals used in marketing. Any claims made—whether by the business or through testimonials—often need solid proof. There’s also heightened sensitivity about ads being attractive to kids, which can lead to outright bans on certain images or styles.

Time and location are other factors regulators watch closely. Ads can’t appear in places where minors are likely to see them, and businesses are often required to include disclaimers or health warnings in their messaging.

Understanding the difference between commercial and noncommercial speech is thus crucial for marijuana businesses. Noncommercial speech, like expressing an opinion about legalization, is generally more protected under both state and federal law. However, when it comes to promoting a product or service, governments have more leeway to regulate or even ban certain types of speech. Because of this, cannabis businesses need to be cautious and may want to consult legal experts before launching a campaign.

Enforcing these rules is another challenge for state agencies. They have to balance constitutional free speech protections with their responsibility to monitor the market. Often, state regulators are short on staff and expertise, making it tough to track ads across platforms like TV, print, social media, and more. To keep up, some states are hiring specialists or bringing in outside help to review marketing content.

Even though some states allow cannabis sales, marijuana is still illegal at the federal level. That means national agencies like the Federal Trade Commission (FTC) and Food and Drug Administration (FDA) can step in if a company makes unproven health claims. Both agencies have acted in the past against cannabis brands exaggerating the benefits of their products.

Legal challenges to these rules are ongoing. In Mississippi, a dispensary owner named Clarence Cocroft argued that his First Amendment rights were violated when he was blocked from advertising. After a federal court ruled against him, he appealed to the U.S. Supreme Court, hoping for a broader recognition of speech rights for cannabis businesses. A win could reshape how these cases are handled in the future.

In Washington, courts have looked at similar issues. In one case, a marijuana retailer challenged the state’s limits on window displays, arguing that their rights under the state constitution were being violated. The court agreed, pointing out inconsistencies in how different types of advertising were treated.

As cannabis laws continue to evolve, so too will the rules around advertising. Businesses in this space need to be strategic, balancing creative marketing with a clear understanding of legal boundaries. Staying informed, compliant, and ready to defend their rights in court might be necessary for long-term success.

The onus is now on firms like Green Thumb Industries Inc. (Cboe CA: GTII) (OTCQX: GTBIF) to find innovative ways to get their messaging to the target audience in light of the stifling restrictions imposed on marijuana advertising.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Trump’s US Attorney Targets Medical Marijuana Firm in Washington

Washington, D.C. has taken several hits since Donald Trump returned to office— massive job losses, seeing its budget shrink by billions, and even facing a downgrade to its bond rating. Now a recent federal move is raising alarms over the city’s handling of cannabis laws.

Ed Martin, the interim U.S. Attorney appointed by Trump, is putting pressure on D.C.’s marijuana industry, challenging an unspoken understanding that federal prosecutors would stay out of local cannabis matters. His warning came in a letter to a medical dispensary, claiming that its operations violate federal law, even though they comply with city regulations.

Martin, a staunch conservative with a history of anti-abortion activism and ties to controversial January 6 defendants, has been a magnet for political disputes since taking the top prosecutor role in D.C. Just in the past week, he’s been under fire for questioning Wikipedia’s nonprofit status and facing backlash over a video undermining his claims about a Jan. 6 figure’s background.

But it’s his stance on cannabis that’s caught many off guard, and not just those on the political left. D.C.’s marijuana rules, while liberal, enjoy support from people across the political spectrum. Martin’s letter to the dispensary Green Theory in the Palisades area came after a neighborhood conflict over the store’s proximity to schools. While city authorities had already addressed the matter, Martin stepped in anyway, citing concerns about protecting children and federal law.

His message carried a clear threat: even fully licensed dispensaries—or landlords renting to them—could face federal prosecution. Advocates warn that such letters, even without legal action, could financially strain small businesses forced to defend themselves.

The larger issue is D.C.’s messy cannabis policy landscape. Because the city isn’t a state, Congress has restricted its ability to set up a proper sales system. While weed is decriminalized, legal sales are confined to medical dispensaries, and even those operate under patchy, often confusing rules.

Critics, like former Councilmember David Grosso, say the city is being targeted unfairly and its limited self-governance is under threat. Others, like attorney Pamela Wexler, see this as a broader effort to weaken local control in favor of federal overreach.

Martin insists he’s just asking questions. Still, his language—and timing—suggest more than mere curiosity. His critics argue this is a revival of the old D.C. dynamic, where federal officials, disconnected from local voters, step in and override community decisions. And for a city still fighting for full autonomy, that’s a troubling sign.

Marijuana industry players like Curaleaf Holdings Inc. (Cboe CA: CURA) (OTCQX: CURLF) will be following how this point of contention in D.C. is resolved since any outcome there could set the pace for what happens in other jurisdictions.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Why Lawmakers Are Wrong to Focus on THC Potency in Marijuana

Getting too high can be a pretty terrible experience. What starts off as a calm, relaxing buzz can quickly spiral into paranoia and anxiety. One minute you’re chilling, the next your mind is racing with worst-case scenarios, and everything feels like it’s falling apart. No one enjoys that kind of high.

Since recreational marijuana became legal in more places, the conversation around THC levels has picked up. People are more concerned about how strong today’s weed is—especially since dispensaries are pushing super-potent strains. A famous example of overconsumption happened in 2014, when journalist Maureen Dowd had a panic episode after consuming too much cannabis-infused chocolate.

Lately, this concern has resurfaced as THC percentages continue to rise and legal markets expand. Some lawmakers want to introduce caps on THC levels, proposing limits between 0.3% and 15% in states like New York, Florida, and Colorado. Meanwhile, many commercial strains already sit above 20%.

However, these efforts to regulate cannabis based on THC percentage might miss the mark. Dr. Peter Grinspoon, a Harvard Medical School physician and author of Seeing Through the Smoke, argues that focusing solely on THC content could harm medical users. For instance, people might consume more low-potency cannabis to achieve the same effect, which could be worse for their lungs. In fact, some research suggests that when cannabis is stronger, people naturally use less.

Grinspoon points out the contradiction; back in the day, marijuana was criticized for being weak and requiring a lot of smoking. Now that it’s stronger, critics say that’s the problem. However, reducing THC might just raise costs for those who rely on cannabis for health reasons.

The complexity of cannabis goes beyond just THC percentage. Brien Hoffhine, who runs cultivation at Loudbird Cannabis in Colorado, says the 2018 Farm Bill didn’t account for how cannabis works chemically. For example, THCA—another compound found in raw marijuana—transforms into THC when heated, but it’s not considered in potency laws. On top of that, there are many cannabinoids besides THC that influence the effects.

Potency labels themselves aren’t always reliable. Different labs can give different results for the same plant, and it’s known in the industry that some companies look for labs that report higher numbers.

Marijuana effects also depend on the user. Everyone’s body reacts differently, influenced by their individual endocannabinoid system. Terpenes—found in all plants—also shape the high, making it more relaxing, energizing, or focused.

Concentrates and distillates with THC levels nearing 95% offer intense effects but often lack the nuanced experience of full-spectrum products. Grinspoon believes that lawmakers have put too much focus on high THC when other compounds like CBD and lesser-known cannabinoids can be just as valuable—especially for medical use. Lawmakers need to understand the full science behind cannabis before creating regulations that make sense.

Marijuana industry actors across the board, including enterprises like Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON), long for a time when all drug policy decisions made or laws enacted are based on rigorous science rather than misconceptions and half-truths. As more studies on marijuana are conducted, more solid data to inform decision making will become available.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Florida House Unanimously Passes Bill Making MMJ Cards Free for Veterans

Florida House legislators have come together in full agreement to pass a measure that will benefit military veterans by removing state fees tied to obtaining medical cannabis cards. Under the new legislation, veterans will no longer need to pay registration or renewal fees for their medical cannabis certifications, effectively making the process free for them.

The measure, House Bill 555, introduced by Republican Representative Alex Andrade, cleared the House with a unanimous 110-0 vote after moving through earlier committee stages. Initially, the proposal aimed to make broader updates to Florida’s medical cannabis system, such as allowing patients to grow cannabis at home and recognizing out-of-state medical cannabis cards.

However, those more ambitious elements were taken out by the House Health Professions and Programs Subcommittee, which replaced the original language with a simplified version focusing only on minor adjustments.

Two main changes remain in the final version. First, instead of having to renew their medical cannabis cards every year, patients would only need to do so every two years. Second, the bill eliminates the $75 fee typically required to register or renew a medical cannabis card for anyone who has served in the military. According to the bill’s updated language, the state would be prohibited from charging veterans for the renewal, issuance, or replacement of these cards.

During the debate on the House floor, Democratic Representative Daryl Campbell expressed his appreciation for the measure, noting that veterans often need medical cannabis at higher rates than the general public. He praised the measure for easing financial stress and simplifying the process, saying it allows people to focus more on their treatment rather than getting caught up in bureaucratic red tape.

If signed into law, the changes would go into effect on July 1.

In related developments, the Florida Senate has advanced other legislation affecting the broader cannabis and hemp landscape. One measure targets hemp-derived products, including THC-infused drinks. The proposal would ban any synthetic cannabinoids, such as delta-8 THC. It would also cap naturally occurring delta-9 THC in hemp products at 5mg per serving and no more than 50mg per package.

The Senate also passed a more expansive agricultural measure this month. Among its provisions is a ban on fungal spores used to grow mushrooms that contain compounds like psilocin and psilocybin. The move followed a House committee’s decision to advance a similar measure in its chamber just one day earlier.

Such efforts by lawmakers to make it easier for military veterans to access medical marijuana products is a move that industry actors like Cresco Labs Inc. (Cboe CA: CL) (OTCQX: CRLBF) would welcome as a progressive approach to increasing access to needed cannabis treatments.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — New Mexico Court Makes Ruling on Insurance Coverage for Medical Cannabis Costs

A federal judge has ruled that health insurance providers in New Mexico aren’t legally required to pay for medical cannabis, even though some state laws suggest they should. This decision underscores the ongoing clash between state-level cannabis initiatives and overarching federal drug policies.

The lawsuit originated from a group of plaintiffs that included individuals enrolled in Medicaid or private insurance plans, along with a licensed cannabis dispensary. They claimed that marijuana used to treat mental and behavioral health conditions should be reimbursed under several New Mexico statutes, including the Behavioral Health Services Act and regulations on insurance practices. Their argument hinged on the idea that these laws collectively obligated insurers to cover medical cannabis.

But the court rejected those arguments, siding with major insurers—Western Sky Community Care Inc., Blue Cross & Blue Shield of New Mexico, and Presbyterian Health Plan Inc. The judge pointed to the state’s Benchmark Plan, which acts as a standard for insurance coverage. That plan doesn’t mention marijuana as a covered treatment and specifically excludes substances that lack FDA approval. Since marijuana has not been approved by the FDA, the court concluded that insurers have no legal duty to pay for it.

Federal law played a significant role in the ruling. The Medicaid Act allows coverage only for medications that have the FDA’s endorsement. Since marijuana is still considered a controlled substance at the federal level and hasn’t received formal medical approval, insurers would be violating federal law if they reimbursed patients for its use.

The plaintiffs referenced a state law that prohibits cost-sharing for certain behavioral health treatments, suggesting that patients shouldn’t bear the expense of medical marijuana. However, the court clarified that this law only applies to services that insurers are already required to cover—which, in this case, does not include cannabis.

There was mention during the case that federal cannabis laws could change in the future, potentially opening the door for insurance coverage. However, the judge noted that until such changes happen, federal restrictions remain in place. Offering coverage now could put insurers at legal risk.

Looking ahead, this might not be the final word. New Mexico legislators introduced a measure aimed at requiring insurance companies to cover medical cannabis in March. If that proposal becomes law, it could significantly shift how cannabis is handled within New Mexico’s health insurance system.

The broader industry, including firms like Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED) operating outside the U.S. hope that needed reforms can be made so that medical cannabis products can be covered by American insurance companies in order to ensure patients aren’t forced to incur high out-of-pocket costs while choosing these products to manage their symptoms.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — The Business and Legal Impact of Inconsistent Marijuana Testing Rules

Marijuana businesses operating legally across different states face a complicated reality when it comes to product testing. Without federal regulations, states have built their own rules around lab licensing, testing requirements, sampling methods, and even how to handle contaminated products.

This patchwork approach creates major headaches for companies, especially those working in multiple states, leading to inconsistent results, unexpected recalls, and financial risks.

In every legal state, cannabis must pass quality testing before reaching consumers. Labs need to be approved at the state level, but the way states license and accredit labs varies widely. Many states require labs to meet ISO standards for accuracy and reliability, while others have created alternative accreditation systems.

Since no nationwide testing methods exist, labs often develop their own procedures to meet local regulations, making it difficult to compare results across different regions.

One major problem is the inconsistency in what marijuana products must be tested for. Microbial contamination is a good example—some states demand zero tolerance for specific bacteria or mold, while others allow small amounts.

Pesticide testing rules also differ. Some states enforce strict bans on any pesticide residue, while others set thresholds, meaning trace amounts might still pass. Heavy metal testing is another area with differences. While most states test for mercury, arsenic, lead, and cadmium, some also require screening for additional metals like nickel and chromium.

THC potency testing is one of the few areas with broad agreement: almost all states require labs to measure THC levels for labeling. Still, states differ on how they calculate and define “Total THC” and whether they require testing for other cannabinoids like CBG or CBN.

Testing also changes depending on the product type. Marijuana flower usually faces the broadest testing requirements, while concentrates and edibles may have modified standards. For instance, concentrates often undergo solvent testing to ensure no harmful extraction chemicals are left behind. However, microbial testing may be relaxed for certain concentrate products since the extraction process can eliminate some microbes.

When it comes to topicals, edibles, and beverages, testing standards diverge even more. Some states believe that if the extract used in an edible passed all testing, the finished product doesn’t need to be retested. Others insist that the final product must be checked again.

Sampling procedures add another layer of inconsistency. Some states allow licensees to collect their own samples, while others require labs or neutral parties to do it to prevent tampering. Sampling sizes also vary: some states base it on a percentage of the batch, others on weight guidelines. These differences affect the reliability of test results and encourage practices like “lab shopping,” where companies look for labs that might deliver more favorable outcomes.

When a batch fails testing, the consequences depend heavily on local rules. Some states require immediate destruction, especially for serious contamination such as banned pesticides. Others allow remediation efforts, giving businesses a chance to fix and retest their products.

For marijuana operators trying to stay compliant, this fragmented system isn’t just a paperwork hassle—it can cause real financial damage. A failed batch, product recall, or lawsuit over testing can cost companies millions. Even when businesses do everything by the book, they might get caught up in recalls caused by lab errors or inconsistent standards.

For instance, Michigan regulators recalled all marijuana products tested over three months by a major laboratory in 2021. More than 400 dispensaries were impacted, and about $229 million worth of products were pulled from shelves.

As the industry evolves, businesses, regulators, and labs need a more unified system with shared testing standards and methods. Standardization would protect consumers, provide more stability for companies, and create a safer, more trustworthy industry overall.

For companies like Trulieve Cannabis Corp. (CBoe CA: TRUL) (OTCQX: TCNNF) that focus on making and selling medical marijuana products, uniform cannabis testing rules and practices are very important since lives can be impacted adversely if this crucial testing phase isn’t uniformly undertaken.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — New York’s Social Equity Program Grapples with Predatory Investors

In 2022, a couple, Kim Stetz and her partner Marq Hayes submitted an application for a Conditional Adult-Use Recreational Dispensary (CAURD) license. Their goal was to open an adult-use marijuana store called Brown Budda in New York.

They were among over 900 applicants hoping to secure a social equity CAURD permit, a surprisingly low number given the state’s history of cannabis-related arrests.

Out of all the applicants, only 32 individuals were initially selected for provisional approval. Fast forward two and a half years and Brown Budda is fully licensed and had even launched delivery operations. However, the municipality they are operating in, Southampton, unexpectedly announced that a special-use license is required for delivery services.

According to Stetz, this demand is inaccurate. Despite disagreeing, they’ve decided to comply with the Town Council’s request and have paused their operations. Meanwhile, the business is sitting on a world-class location with a 15-year lease, yet facing opposition simply because the new Town Council isn’t thrilled with the choices their predecessors made.

On the financial front, the Brown Budda founders have faced many questionable offers. Wealthy investors frequently approach them, offering funding but demanding total ownership rather than fair loan terms or reasonable equity stakes.

Potential financiers are asking for half or more of the business once their conditional license transitions to a general license in 2028, or if they ever decide to sell. The couple has already spent over $50,000 on legal and consulting fees just to maintain full ownership. They have decided to hold out for a fair partnership or, ideally, find an affordable loan—an option that is slowly becoming available for marijuana enterprises.

Throughout this struggle, Stetz has noticed that investors appear far more focused on their personal profits than on supporting the individuals who have built the business from the ground up. This situation has made them question whether the social equity goals that New York intended with its cannabis rollout are being honored.

Thankfully, the Office of Cannabis Management (OCM) recently introduced the Trade Practices Bureau (TPB) to crack down on shady practices like predatory lending and fraudulent deals that could crush small cannabis businesses. Their mission is to protect the spirit of social equity and make sure big money doesn’t steamroll the entrepreneurs who were meant to benefit.

Real estate and funding challenges have put CAURD license holders in tough spots, often forcing them into unfair deals. Until things truly change, cannabis entrepreneurs like Brown Budda are left fielding shady offers, cannabis-style.

For those entering the cannabis space, Stetz encourages deep reflection on personal motives, advising newcomers to prioritize community and fairness over pure profit. Her advice is simple: listen to license holders and offer them genuinely fair deals based on their needs.

Established marijuana companies like Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) will be hoping that any loopholes allowing predatory investors to infiltrate the social equity program in New York State are plugged so that those who are earmarked as beneficiaries of that program do benefit from it.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — How Marijuana Descheduling or Rescheduling Would Impact the Industry

The potential shift in how cannabis is classified under federal law is stirring up discussions about the future of the cannabis industry and the possibility of opening up interstate trade. Although many U.S. states have already legalized cannabis for recreational, medical use, or both, it’s still illegal at the federal level, which limits the ability to create a unified national market.

According to Robin Goldstein, head of the Cannabis Economics Group at UC Davis, the direction of the sector is largely dependent on what the federal government does next. Whether cannabis will be reclassified or completely removed from the list of controlled substances remains unclear, leaving many cannabis business owners uncertain about what lies ahead.

Frank Colombo, a managing director at Viridian Capital Advisors, a firm focused on cannabis investments, expressed doubt that marijuana would be removed from the controlled substances list anytime soon. He said he’d be surprised if it happened in the next decade, let alone the next five years.

Industry experts have mixed views on how rescheduling—moving cannabis to a less restrictive category—versus descheduling—removing it entirely—would impact the sector. If cannabis gets moved to Schedule III, it would likely allow marijuana operators to access tax breaks that they currently can’t use due to Section 280E of the IRS code.

However, this wouldn’t necessarily change how marijuana is grown, sold, or transported across state lines. For those things to change, Congress would need to pass additional laws such as the SAFE Banking Act.

Legalizing interstate cannabis commerce would also bring up new questions about taxation. States would need to figure out how to handle products being imported from other regions. At the same time, any expansion into the pharmaceutical side of the market would likely require FDA approval, which is a costly and lengthy process with uncertain returns.

Goldstein points out that even if marijuana-based drugs were approved, most generic cannabis products already on the market couldn’t be patented, making it hard to compete with the profits seen in traditional pharmaceuticals.

If marijuana were completely descheduled, it would likely open the door to interstate commerce, but it could also trigger federal regulations and taxes. This might slow growth and increase costs for operators, giving illegal operators an edge due to their lower prices.

According to Colombo, states with lower cultivation costs, like Oklahoma, California, Washington, and Oregon, could benefit most if national trade becomes legal. On the flip side, companies that invested in indoor grow operations in states with poor outdoor growing conditions could be hurt. State governments, too, might see a drop in tax revenue if local cultivation shrinks.

Industry actors like Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) now have the task of preparing for both scenarios so that if rescheduling or descheduling happens, they are ready for it rather than scrambling to cope once the change has been made.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Trucking Industry Says Outdated Federal Rules, Cannabis Testing Are Causing Trucker Shortages

A new report from two trucking industry companies highlights a growing problem in the field: a serious shortage of drivers, estimated at around 80,000 last year. One of the key reasons behind this, the report says, is the number of drivers testing positive for cannabis under the U.S. Department of Transportation’s (DOT) strict drug policies.

The paper— “Cannabis, Compliance and Driver Retention”—was produced by Fleetworthy and FreightWaves. It explains that most qualified drivers are being sidelined due to positive drug test results, often because they are unaware that federal rules don’t recognize cannabis legalization in individual states.

As more states move to legalize cannabis and its use becomes socially acceptable, the trucking industry faces new challenges in managing safety regulations. The report also discusses the rise of CBD and cannabis-based products and how current DOT rules haven’t adapted to reflect today’s legal landscape.

Under current DOT guidelines, truckers are tested for drugs before employment, randomly while on the job, after accidents, or when there is suspicion of impairment. If a driver fails a test, they are immediately taken off the road and must go through a process that includes evaluations, follow-up testing, and counseling. While some states, like Minnesota, offer protections for first-time offenses, the process often ends careers.

When a driver is removed, companies lose experienced personnel and must invest heavily in recruiting and training replacements, which increases costs and stress on the system.

The report suggests that reclassifying cannabis under federal law—from a Schedule I to a Schedule III substance—could help, especially by reducing stigma and acknowledging its medical use. However, such a change wouldn’t automatically affect DOT testing requirements, since driving is a high-risk job.

To help reduce the impact on drivers and improve retention, the report recommends increasing education around cannabis policies, offering better training, and updating testing methods. For instance, improved CBD labeling could help drivers avoid accidental THC exposure. More accurate drug tests, such as those using hair and saliva samples, could also be fairer than the standard urine tests, which can detect drug use long after the effects have worn off.

Though oral fluid testing was approved by DOT policy changes in 2023, the system isn’t fully operational yet due to delays in certifying testing labs.

Ultimately, the paper emphasizes the importance of keeping the conversation going among trucking companies, government bodies, and drivers to find practical solutions that balance safety and fairness.

Federal reforms to align state policies with federal law would allow more truckers to retain their jobs while benefiting from the cannabis products sold by licensed companies like Tilray Brands Inc. (NASDAQ: TLRY) (TSX: TLRY) and other domestic firms.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com